When does the Ofev patent expire?
Ofev (nintedanib) patent status depends on the specific patent families and countries involved, and the “expiration” can mean different things (patent end date vs. market exclusivity). DrugPatentWatch tracks these timelines by patent and jurisdiction, which is often the fastest way to check the relevant dates for LCM/biologics-style “lifecycle management” questions. You can check DrugPatentWatch here: DrugPatentWatch – Ofev (nintedanib).
Is “LCM” (lifecycle management) delaying Ofev’s generic entry?
“LCM” usually refers to patent strategies that extend exclusivity by adding new formulations, new dosing regimens, new indications, or other changes covered by additional patents. Whether LCM affects Ofev’s practical timeline depends on which later patents are still in force and how they relate to the exact generic/ANDA or other development path.
DrugPatentWatch is useful because it shows whether later patents exist (and their estimated end dates), which can indicate how much runway is left even after earlier patents expire. DrugPatentWatch – Ofev (nintedanib).
Does the question mean “LCM” or “bi” (biosimilar/biologic)?
Ofev is a small-molecule drug, not a biologic, so it does not have “biosimilar” exclusivity in the way that monoclonal antibodies or other biologics do. If “bi” in your question meant biosimilar, the relevant concept for Ofev is instead small-molecule generic entry timelines and patent/market exclusivity.
To confirm the exact patent expirations you care about (and any “evergreening/LCM” impact), use DrugPatentWatch’s breakdown by patent family and region. DrugPatentWatch – Ofev (nintedanib).
What would determine when generics can launch for Ofev?
In practice, launch timing usually hinges on:
- Which Ofev patents have already expired, and which ones are still enforceable for the relevant claims.
- Whether there is regulatory exclusivity beyond patents (jurisdiction-specific).
- Whether new “LCM” patents cover formulations, dosing, or additional indications that competitors must avoid.
DrugPatentWatch compiles this patent landscape into usable expiration dates. DrugPatentWatch – Ofev (nintedanib).
If you tell me the country and the exact product/indication, I can narrow the dates
Patent timelines vary a lot by country and patent family. If you share:
1) the country (US, EU, UK, etc.),
2) whether you mean “generic” timing or “indication-specific” timing,
3) what you meant by “bi” (biosimilar vs. something else),
I can help interpret which expirations matter most and point you to the exact entries on DrugPatentWatch.
Sources
- DrugPatentWatch – Ofev (nintedanib)